Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer
作者： A.F.C. Okines , A.R. Norman , P. McCloud , Y.-K. Kang , D. Cunningham
关键词: Medicine 、 Fluorouracil 、 Proportional hazards model 、 Capecitabine 、 Internal medicine 、 Odds ratio 、 Hazard ratio 、 Survival analysis 、 Surgery 、 Oncology 、 Combination chemotherapy 、 Progression-free survival
摘要: Methods: Individual patient data were collected on all patients randomised within the trials (n = 1318). Kaplan-Meier survival curves generated and log-rank test was used to compare OS PFS between receiving 5-FU combinations capecitabine combinations. Stepwise multivariate Cox regression analysis calculate corrected hazard ratios (HRs) 95% confidence intervals (CIs) for PFS. Logistic objective response rate. Forest plots with tests of heterogeneity generated. Results: superior in 654 treated compared 664 combinations; HR 0.87 (95% CI 0.77-0.98, P 0.02). Poor performance status, age < 60 metastatic disease independent predictors poor survival. There no significant difference treatment groups analysis. Assessable significantly more likely have an than those odds ratio 1.38 1.10-1.73, 0.006). Conclusion: is advanced oesophago-gastric cancer.
annalsofoncology.org
oup.com
oxfordjournals.org
core.ac.uk
paperity.org参考文章(31)
M.M Borner, P Schöffski, R de Wit, F Caponigro, G Comella, A Sulkes, G Greim, G.J Peters, K van der Born, J Wanders, R.F de Boer, C Martin, P Fumoleau, Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. European Journal of Cancer. ,vol. 38, pp. 349- 358 ,(2002) , 10.1016/S0959-8049(01)00371-9
Hideo Ishitsuka, Capecitabine: preclinical pharmacology studies. Investigational New Drugs. ,vol. 18, pp. 343- 354 ,(2000) , 10.1023/A:1006497231579
M Mackean, A Planting, C Twelves, J Schellens, D Allman, B Osterwalder, B Reigner, T Griffin, S Kaye, J Verweij, Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. Journal of Clinical Oncology. ,vol. 16, pp. 2977- 2985 ,(1998) , 10.1200/JCO.1998.16.9.2977
A Webb, D Cunningham, J H Scarffe, P Harper, A Norman, J K Joffe, M Hughes, J Mansi, M Findlay, A Hill, J Oates, M Nicolson, T Hickish, M O'Brien, T Iveson, M Watson, C Underhill, A Wardley, M Meehan, Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. Journal of Clinical Oncology. ,vol. 15, pp. 261- 267 ,(1997) , 10.1200/JCO.1997.15.1.261
Udo Vanhoefer, Philippe Rougier, Hansjochen Wilke, Michel P. Ducreux, Angel J. Lacave, Eric Van Cutsem, Manfred Planker, José Guimaraes Dos Santos, Pascal Piedbois, Bernard Paillot, Heinrich Bodenstein, Hans-Jochen Schmoll, Harry Bleiberg, Bernard Nordlinger, Marie-Laure Couvreur, Benoit Baron, Jacques A. Wils, Final Results of a Randomized Phase III Trial of Sequential High-Dose Methotrexate, Fluorouracil, and Doxorubicin Versus Etoposide, Leucovorin, and Fluorouracil Versus Infusional Fluorouracil and Cisplatin in Advanced Gastric Cancer: A Trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group Journal of Clinical Oncology. ,vol. 18, pp. 2648- 2657 ,(2000) , 10.1200/JCO.2000.18.14.2648
E. L. Kaplan, Paul Meier, Nonparametric Estimation from Incomplete Observations Springer Series in Statistics. ,vol. 53, pp. 319- 337 ,(1992) , 10.1007/978-1-4612-4380-9_25
Eun Kyung Cho, Woon Ki Lee, Seok-Ah Im, Soon Nam Lee, Se Hoon Park, Soo-Mee Bang, Dong Kyun Park, Yeon Ho Park, Dong Bok Shin, Jae Hoon Lee, None, A Phase II Study of Epirubicin, Cisplatin and Capecitabine Combination Chemotherapy in Patients with Metastatic or Advanced Gastric Cancer Oncology. ,vol. 68, pp. 333- 340 ,(2005) , 10.1159/000086972
Bruno Reigner, Karen Blesch, Erhard Weidekamm, Clinical Pharmacokinetics of Capecitabine Clinical Pharmacokinectics. ,vol. 40, pp. 85- 104 ,(2001) , 10.2165/00003088-200140020-00002
Y H Park, B-S Kim, B-Y Ryoo, S H Yang, A phase II study of capecitabine plus 3-weekly oxaliplatin as first-line therapy for patients with advanced gastric cancer. British Journal of Cancer. ,vol. 94, pp. 959- 963 ,(2006) , 10.1038/SJ.BJC.6603046
M Miwa, M Ura, M Nishida, N Sawada, T Ishikawa, K Mori, N Shimma, I Umeda, H Ishitsuka, Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue European Journal of Cancer. ,vol. 34, pp. 1274- 1281 ,(1998) , 10.1016/S0959-8049(98)00058-6